Ras
As proteínas Ras são pequenas GTPases que atuam como interruptores moleculares na via de sinalização MAPK, controlando o crescimento, a diferenciação e a sobrevivência celular. Ras ativado inicia uma cascata de sinalização que inclui Raf, MEK e ERK, levando a várias respostas celulares. As mutações nos genes Ras são comuns em cânceres, tornando Ras um foco importante da pesquisa sobre o câncer. Na CymitQuimica, oferecemos uma variedade de moduladores de Ras para apoiar sua pesquisa em biologia do câncer, transdução de sinais e desenvolvimento terapêutico.
Foram encontrados 155 produtos de "Ras"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
RGT-018
CAS:<p>RGT-018 is a potent oral SOS1 inhibitor with antitumor properties. It exerts its anticancer activity by inhibiting KRAS activation, thereby hindering cancer cell proliferation.</p>Fórmula:C27H24F3N7O2Cor e Forma:SolidPeso molecular:535.52KRAS inhibitor-32
CAS:<p>KRAS inhibitor-32 (compound 139A) is a KRAS inhibitor utilized in cancer research.</p>Fórmula:C29H35FN10OS2Cor e Forma:SolidPeso molecular:622.78BMS-214662
CAS:<p>BMS-214662 is a selective farnesyl transferase inhibitor with anti-tumor activity, used in research on pancreatic cancer, head and neck cancer, and lung cancer.</p>Fórmula:C25H23N5O2S2Pureza:99.58% - 99.58%Cor e Forma:SolidPeso molecular:489.61pan-KRAS degrader 1
CAS:<p>Pan-KRAS degrader 1 (Compound 1) is a broad-spectrum KRAS degrader, exhibiting an inhibitory constant Ki value of 25 nM against KRASG12V as determined by surface plasmon resonance (SPR). Additionally, this compound demonstrates antitumor activity.</p>Fórmula:C22H26N8OSCor e Forma:SolidPeso molecular:450.56KRAS inhibitor-37
CAS:<p>KRAS inhibitor-37 (compound 2) is a potent inhibitor of KRAS, exhibiting low dissociation constants (KD) with various KRAS mutations: wild type (0.004 nM), G12D (0.041 nM), G12C (0.019 nM), and G12V (0.144 nM). This compound effectively inhibits cell proliferation, demonstrating half-maximal inhibitory concentrations (IC50) ranging from <2 nM to 14 nM in H358, SW620, and PANC08.13 cell lines. KRAS inhibitor-37 holds potential for cancer research applications.</p>Fórmula:C32H33ClFN7O3Cor e Forma:SolidPeso molecular:618.10KRas G12C inhibitor 2
CAS:<p>KRas G12C inhibitor 2 is a compound that inhibits KRas G12C.</p>Fórmula:C32H37N7O3Pureza:98%Cor e Forma:SolidPeso molecular:567.68Dorrigocin A
CAS:<p>Dorrigocin A, an analog of Migrastatin, inhibits the carboxymethyltransferase involved in Ras processing, reversing the morphology of Ras-transformed NIH/3T3 cells. Dorrigocin A holds potential for research as an anticancer and anti-arthritis agent.</p>Fórmula:C27H41NO8Cor e Forma:SolidPeso molecular:507.616ZCL279
CAS:<p>ZCL279 is a small molecule modulator (SMM) that inhibits the interaction between CDC42 and intersectin (ITSN). At lower concentrations (<10 μM), ZCL279 activates Cdc42, a cytoplasmic small GTPase in the Ras superfamily, while at higher concentrations (<10 μM) it significantly inhibits it.</p>Fórmula:C24H18N2O7S2Cor e Forma:SolidPeso molecular:510.539KRAS inhibitor-31
CAS:<p>KRAS inhibitor-31 (compound 33), a potent agent targeting KRAS, exhibits K D (SPR) values of 0.019 nM for KRas G12D, 0.019 nM for KRas G12C, and 0.096 nM for KRas G12V, illustrating its efficacy across these variants.</p>Fórmula:C33H30F3N5O4Cor e Forma:SolidPeso molecular:617.62XMU-MP-9
CAS:<p>XMU-MP-9, a bifunctional compound, targets the C2 domain of Nedd4-1 and the allosteric site of K-Ras. It enhances the interaction and induces conformational changes within the Nedd4-1/K-Ras complex. Furthermore, XMU-MP-9 facilitates the ubiquitination and degradation of various K-Ras mutants and inhibits the proliferation of cells with these mutants. This compound is useful in cancer research.</p>Fórmula:C19H13ClFN3OSCor e Forma:SolidPeso molecular:385.84AM-001
CAS:AM-001 is a non-competitive inhibitor of Epac1, preventing the activation of its downstream effector Rap1 in cultured cells. This compound is utilized in research related to cardiac diseases.Fórmula:C24H16FN3OS2Cor e Forma:SolidPeso molecular:445.53KRAS inhibitor-35
CAS:<p>KRAS inhibitor-35 (compound 72) is a KRAS inhibitor with an IC50 of 2 nM, utilized in tumor research.</p>Fórmula:C38H32F4N6O3SCor e Forma:SolidPeso molecular:728.76KRAS inhibitor-41
CAS:<p>KRAS inhibitor-41 is a KRAS inhibitor with an IC50 value of less than 0.01 μM for both KRAS G12D and KRAS G12V mutations. It effectively inhibits RAS mutant cell lines GP2D (KRAS-G12D) and SW620 (KRAS-G12V). KRAS inhibitor-41 is applicable for cancer research.</p>Fórmula:C30H37FN10OSCor e Forma:SolidPeso molecular:604.745Sosimerasib
CAS:<p>Sosimerasib is an inhibitor of the kirsten rat sarcoma viral oncogene homolog (KRAS) and exhibits antitumor activity.</p>Fórmula:C36H39ClFN7O4Cor e Forma:SolidPeso molecular:688.191KRAS G12D inhibitor 28
CAS:<p>KRAS G12D inhibitor 28 (Compound 1) is an inhibitor of KRAS G12D and can be utilized in cancer research.</p>Fórmula:C35H32Cl2FN5OCor e Forma:SolidPeso molecular:628.57
